Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 4/20 | 0.44 |
| ▸ | F3 | P13726 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | TOP1 | P11387 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855467 | 1.00 | FAAH (0.46) | FAAHTRPV1F7F3ALDH1A1 | |
| SCHEMBL55770 | 0.97 | — | — | |
| SCHEMBL55769 | 0.97 | — | — | |
| SCHEMBL1768071 | 0.97 | — | — | |
| Bromide SCHEMBL5219342 | 0.94 | — | — | |
| SCHEMBL960733 | 0.94 | FAAH (0.52) | FAAHTRPV1F7F3ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8386802 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL5250241 | 0.94 | — | — | |
| SCHEMBL25415786 | 0.91 | FAAH (0.56) | FAAHTRPV1F7F3CYP19A1 | |
| SCHEMBL860470 | 0.91 | FAAH (0.56) | FAAHTRPV1F7F3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-110780014-B | Method for identifying gall-containing wood by gas chromatography-mass spectrometry technology | 莆田市家具产品质量监督检验中心 | 2022-07-19 | — | — | CN | claimed |
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | ALKALAY RACHEL (IL) | 2024-11-28 | — | — | US | disclosed |
| CN-114668824-B | Application of alpinia zerumbet essential oil | 昆明理工大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20230181665-A1 | TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASES | Novel Concepts Medical Ltd (IL) | 2023-06-15 | — | — | US | disclosed |
| EP-0734764-B1 | Catalyst and process for producing oxirane compounds | SUMITOMO CHEMICAL CO (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-5840650-A | IMPREGNATING SILICON COMPOUND WITH A TITANIUM COMPOUND IN A SOLVENT; DESOLVENTIZING; WASHING; CALCINING | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0734764-A2 | Catalyst and process for producing oxirane compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
| WO-1993004057-A2 | HERBICIDES CONTAINING 3-AMINOBENZO[B]THIOPHENES AS AN ANTIDOTE | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-04 | — | — | WO | disclosed |
| US-4303586-A | Catalytic epoxidation of olefins | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1981-12-01 | — | — | US | disclosed |
| US-4303587-A | Catalytic epoxidation of olefins | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | TPO, TNF, ADAMTS13 | FAAH 1981/4885TRPV1 1006/4885F7 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.